CN103118699A - 白介素-22在治疗病毒性肝炎中的应用 - Google Patents

白介素-22在治疗病毒性肝炎中的应用 Download PDF

Info

Publication number
CN103118699A
CN103118699A CN2011800417372A CN201180041737A CN103118699A CN 103118699 A CN103118699 A CN 103118699A CN 2011800417372 A CN2011800417372 A CN 2011800417372A CN 201180041737 A CN201180041737 A CN 201180041737A CN 103118699 A CN103118699 A CN 103118699A
Authority
CN
China
Prior art keywords
dimer
monomer
hepatitis
comonomer
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011800417372A
Other languages
English (en)
Other versions
CN103118699B (zh
Inventor
严孝强
黄智华
杨红舟
黄予良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yiyi biomedical development (Shanghai) Co.,Ltd.
Original Assignee
Generon Shanghai Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp Ltd filed Critical Generon Shanghai Corp Ltd
Priority to CN201180041737.2A priority Critical patent/CN103118699B/zh
Priority to CN201410612763.1A priority patent/CN104479026B/zh
Publication of CN103118699A publication Critical patent/CN103118699A/zh
Application granted granted Critical
Publication of CN103118699B publication Critical patent/CN103118699B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种人白介素-22的二聚体及其药物组合物。本发明还公开了人白介素-22或其二聚体在制备治疗病毒性肝炎的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201180041737.2A 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用 Active CN103118699B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201180041737.2A CN103118699B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用
CN201410612763.1A CN104479026B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2010102683207A CN102380091A (zh) 2010-08-31 2010-08-31 白介素-22在治疗病毒性肝炎中的应用
CN201010268320.7 2010-08-31
CN201180041737.2A CN103118699B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用
PCT/CN2011/079124 WO2012028089A1 (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410612763.1A Division CN104479026B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用

Publications (2)

Publication Number Publication Date
CN103118699A true CN103118699A (zh) 2013-05-22
CN103118699B CN103118699B (zh) 2014-11-19

Family

ID=45772162

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010102683207A Pending CN102380091A (zh) 2010-08-31 2010-08-31 白介素-22在治疗病毒性肝炎中的应用
CN201180041737.2A Active CN103118699B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用
CN201410612763.1A Active CN104479026B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010102683207A Pending CN102380091A (zh) 2010-08-31 2010-08-31 白介素-22在治疗病毒性肝炎中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410612763.1A Active CN104479026B (zh) 2010-08-31 2011-08-30 白介素-22在治疗病毒性肝炎中的应用

Country Status (14)

Country Link
US (2) US8945528B2 (zh)
EP (2) EP2633865B1 (zh)
JP (2) JP5907970B2 (zh)
CN (3) CN102380091A (zh)
AU (1) AU2011298556B2 (zh)
CA (1) CA2809900C (zh)
DK (1) DK2633865T3 (zh)
ES (1) ES2658309T3 (zh)
HK (1) HK1185552A1 (zh)
HU (1) HUE036564T2 (zh)
PL (1) PL2633865T3 (zh)
PT (1) PT2633865T (zh)
TR (1) TR201802587T4 (zh)
WO (1) WO2012028089A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705160A (zh) * 2013-11-07 2016-06-22 健能隆医药技术（上海）有限公司 Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP3054978B1 (en) * 2013-10-08 2019-03-06 Georgia State University Research Foundation, Inc. Compositions including il-18 and il-22 and their use in anti-viral therapies
CN112386680B (zh) * 2013-11-07 2024-05-24 纪念斯隆-凯特林癌病中心 在胃肠道移植物抗宿主病的治疗中使用il-22的方法
US11964002B2 (en) * 2017-02-28 2024-04-23 Vib Vzw Means and methods for oral protein delivery
US20230079150A1 (en) * 2020-02-14 2023-03-16 Evive Biotechnology (Shanghai) Ltd Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2023144393A1 (en) * 2022-01-28 2023-08-03 Fundació Centre De Regulació Genòmica Therapeutic cytokines and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US359117A (en) 1887-03-08 william whakton
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE3889546T2 (de) 1987-12-21 1994-09-08 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
EP0394538B1 (en) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh A yeast cell of the genus schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
IL122385A (en) 1995-06-07 2001-01-11 Alkermes Inc Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030003545A1 (en) 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
EP1131333B1 (en) 1998-10-26 2010-06-02 Wyeth a Corporation of the State of Delaware ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101027079B (zh) * 2004-10-12 2011-08-17 美国蛋白质公司 嵌合蛋白
CN100515491C (zh) 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009041734A1 (ja) * 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. ヒトトロンボポエチン受容体に対するアゴニスト抗体
CN101225110B (zh) 2007-10-23 2010-10-20 中国人民解放军军事医学科学院基础医学研究所 人白细胞介素-22突变体及其构建方法和应用
RU2503460C2 (ru) 2007-11-07 2014-01-10 Дженентек Инк. Применение противомикробного полипептида для лечения микробных нарушений
US20130121959A1 (en) 2010-01-13 2013-05-16 Joseph R. Maxwell Il-22-fc and hepcidin activity
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
JP5044060B2 (ja) 2010-12-28 2012-10-10 パナソニック株式会社 非水電解質二次電池およびその製造方法
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
JP6188355B2 (ja) 2013-03-06 2017-08-30 キヤノン株式会社 放射線撮影装置、補正方法及びプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786551B2 (en) 2007-08-06 2020-09-29 Generon (Shanghai) Corporation Ltd. Use of interleukin-22 in the treatment of fatty liver disease
CN105705160A (zh) * 2013-11-07 2016-06-22 健能隆医药技术（上海）有限公司 Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
US10543169B2 (en) 2013-11-07 2020-01-28 Generon (Shanghai) Corporation Ltd. Use of IL-22 dimer in manufacture of a medicament for intravenous administration
CN105705160B (zh) * 2013-11-07 2020-02-07 健能隆医药技术（上海）有限公司 Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
US11654104B2 (en) 2013-11-07 2023-05-23 Evive Biotechnology (Shanghai) Ltd Use of IL-22 dimer in manufacture of a medicament for intravenous administration
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis

Also Published As

Publication number Publication date
AU2011298556B2 (en) 2015-04-16
CA2809900A1 (en) 2012-03-08
HUE036564T2 (hu) 2018-07-30
US20150202267A1 (en) 2015-07-23
CA2809900C (en) 2018-08-21
CN104479026B (zh) 2019-02-12
CN104479026A (zh) 2015-04-01
US20130171100A1 (en) 2013-07-04
DK2633865T3 (en) 2018-02-26
TR201802587T4 (tr) 2018-03-21
WO2012028089A1 (zh) 2012-03-08
EP2633865A1 (en) 2013-09-04
PL2633865T3 (pl) 2018-05-30
AU2011298556A1 (en) 2013-04-04
JP2016128475A (ja) 2016-07-14
HK1185552A1 (zh) 2014-02-21
CN103118699B (zh) 2014-11-19
ES2658309T3 (es) 2018-03-09
JP5907970B2 (ja) 2016-04-26
JP2013536254A (ja) 2013-09-19
US8945528B2 (en) 2015-02-03
CN102380091A (zh) 2012-03-21
EP2633865B1 (en) 2017-12-27
PT2633865T (pt) 2018-03-13
US9629898B2 (en) 2017-04-25
EP3332798A1 (en) 2018-06-13
EP2633865A4 (en) 2014-11-12
JP6325585B2 (ja) 2018-05-16

Similar Documents

Publication Publication Date Title
CN103118699A (zh) 白介素-22在治疗病毒性肝炎中的应用
CN104066440B (zh) 白介素-22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
CA2695734C (en) Use of interleukin-22 in the treatment of fatty liver disease
CN103079586A (zh) G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
JP4024366B2 (ja) ポリペプチド
CN100515491C (zh) 白介素-22的医药用途
Tian et al. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris
JP6475698B2 (ja) 組換えマンネンタケ免疫調節タンパク質とヒト血清アルブミンの融合タンパク質及びその製造方法と応用
CN103732240A (zh) G-csf二聚体在制备治疗神经退行性疾病药物中的应用
AU6175800A (en) Interferon tau mutants and methods for making them
CN102219850A (zh) 新的长效glp-1化合物
CN101219208B (zh) 白介素-22的医药用途
KR20210101145A (ko) 페길화된 IgE-의존적 히스타민 방출인자(HRF) 결합 펩타이드 및 이의 용도
CN1258740A (zh) 表达人白细胞介素12的重组腺病毒及其制法和用途
CN109627343A (zh) 长效细胞因子基因衍生物融合蛋白
JP2007143555A (ja) ポリペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185552

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1185552

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: 201203 room 307, Lane 1011, Halley Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai

Patentee after: Yiyi biomedical development (Shanghai) Co.,Ltd.

Address before: 201203 room 307, Lane 1011, Halley Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai

Patentee before: GENERON (SHANGHAI) Corp.,Ltd.

CP01 Change in the name or title of a patent holder